Advertisement

Mechanism of action of anti-inflammatory drugs: an overview

  • J. R. Vane
  • R. M. Botting

Abstract

Among the many mediators of inflammation, the prostaglandins (PGs) are of great importance. They are released by almost any type of chemical or mechanical stimulus. The key enzyme in their synthesis is prostaglandin endoperoxide synthase (PGHS) or cyclooxygenase (COX) which possesses two catalytic sites. The first, a cyclooxygenase active site, converts arachidonic acid to the endoperoxide PGG2. The second, a peroxidase active site, then converts the PGG2 to another endoperoxide PGH2. PGH2 is further processed by specific isomerases to form PGs, prostacyclin and thromboxane A2. Of the PGs, PGE2 and prostacyclin are the main inflammatory mediators. Cyclooxygenase activity has long been studied in preparations from sheep seminal vesicles and a purified, enzymatically-active COX was isolated in 19761. We now know that COX exists in at least two isoforms, COX-1 and COX-2.

Keywords

Familial Adenomatous Polyposis Prostaglandin Endoperoxide Inducible Cyclooxygenase Human Fetal Membrane Sheep Seminal Vesicle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hemler M, Lands WEM, Smith WL. Purification of the cyclooxygenase that forms prostaglandins: Demonstration of two forms of iron in the holoenzyme. J Biol Chem. 1976; 251:5575–5579.PubMedGoogle Scholar
  2. 2.
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirinlike drugs. Nature. 1971; 231: 232–235.Google Scholar
  3. 3.
    Higgs GA, Vane JR, Hart FD, Wojtulewski JA. Effects of anti-inflammatory drugs on prostaglandins in rheumatoid arthritis. In: Robinson HJ, Vane JR eds. Prostaglandin Synthase Inhibitors. New York, Raven Press; 1974: 165–173.Google Scholar
  4. 4.
    Picot D, Loll PJ, Garavito RM. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994; 367: 243–249.PubMedCrossRefGoogle Scholar
  5. 5.
    Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct Biol. 1996; 3: 927–933.PubMedCrossRefGoogle Scholar
  6. 6.
    Mancini JA, Vickers PJ, O’Neill GP, Boily C, Falgueyret J-P, Riendeau D. Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by non-steroidal anti-inflammatory drugs. Mol Pharmacol. 1997; 51: 52–60.PubMedGoogle Scholar
  7. 7.
    Wong E, Bayly C, Waterman HL, Riendeau D, Mancini JA. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 to Arg and Ile523 to Val mutation. J Biol Chem. 1997; 272: 9280–9286.PubMedCrossRefGoogle Scholar
  8. 8.
    Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663–665.PubMedCrossRefGoogle Scholar
  9. 9.
    Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature. 1980; 284: 271–273.PubMedCrossRefGoogle Scholar
  10. 10.
    Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 1991; 5: 2304–2312.PubMedGoogle Scholar
  11. 11.
    Raz A, Wyche A, Needleman, P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA. 1989; 86: 1657–1661.PubMedCrossRefGoogle Scholar
  12. 12.
    Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990; 265: 16737–16740.PubMedGoogle Scholar
  13. 13.
    Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest. 1990; 86: 1375–1379.PubMedCrossRefGoogle Scholar
  14. 14.
    Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991; 88: 2692–2696.PubMedCrossRefGoogle Scholar
  15. 15.
    Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: A new target for non-steroidal anti-inflammatory drugs. Drug Dev Res. 1992; 25: 249–265.CrossRefGoogle Scholar
  16. 16.
    O’Banion MK, Sadowski HB, Winn V, Young DA. A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991; 266: 23261–23267.PubMedGoogle Scholar
  17. 17.
    Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991; 26: 12866–12872.Google Scholar
  18. 18.
    Sirois J, Richards JS. Purification and characterisation of a novel, distinct, isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem. 1992; 267; 6382–6388.PubMedGoogle Scholar
  19. 19.
    Vane J. Towards a better aspirin. Nature. 1994; 367; 215–216.PubMedCrossRefGoogle Scholar
  20. 20.
    DeWitt DL. Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim Biophys Acta. 1991; 1083: 121–134.PubMedCrossRefGoogle Scholar
  21. 21.
    Wu KK, Sanduja R, Tsai A-L, Ferhanoglu B, Loose-Mitchell DS. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci USA. 1991; 88: 2384–2387.PubMedCrossRefGoogle Scholar
  22. 22.
    Kargman S, Charleson S, Cartwright M et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts. Gastroenterology. 1996; 111:445–454.PubMedCrossRefGoogle Scholar
  23. 23.
    Langenbach R, Morham SG, Tiano HF et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995; 83: 483–492.PubMedCrossRefGoogle Scholar
  24. 24.
    Cohn SM, Schloemann S, Tessner T, Seibert K, Stenson WF. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest. 1997; 99: 1367–1379.PubMedCrossRefGoogle Scholar
  25. 25.
    Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997; 57: 1276–1280.PubMedGoogle Scholar
  26. 26.
    Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991; 325: 1593–1596.PubMedCrossRefGoogle Scholar
  27. 27.
    Luk GD. Prevention of gastrointestinal cancer — the potential role of NSAIDs in colorectal cancer. Schweiz Med Wochenschr. 1996; 126; 801–812.PubMedGoogle Scholar
  28. 28.
    Nugent KP, Spigelman AD, Phillips RKS. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum. 1996; 39: 659–662.PubMedCrossRefGoogle Scholar
  29. 29.
    Kutchera W, Jones DA, Matsunami N et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancenEvidence for a transcriptional effect. Proc Natl Acad Sci USA. 1996; 93: 4816–4820.PubMedCrossRefGoogle Scholar
  30. 30.
    Gustafson-Svärd C, Lilja I, Halböök O, Sjödahl R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut. 1996; 38: 79–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Tsujii M, Kawako S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997; 94: 3336–3340.PubMedCrossRefGoogle Scholar
  32. 32.
    Sheng H, Shao J, Kirkland SC et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997; 99: 2254–2259.PubMedCrossRefGoogle Scholar
  33. 33.
    Oshima M, Dinchuk JE, Kargman SL et al. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2(COX-2). Cell. 1996; 87: 803–809.PubMedCrossRefGoogle Scholar
  34. 34.
    Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994; 94: 2504–2510.PubMedCrossRefGoogle Scholar
  35. 35.
    Nüsing RM, Klein T, Pfeilschifter J, Ullrich V. Effect of cyclic AMP and prostaglandin E2 on the induction of nitric oxide-and prostanoid-forming pathways in cultured rat mesangial cells. Biochem J. 1996; 313: 617–623.PubMedGoogle Scholar
  36. 36.
    Morham SG, Langenbach R, Loftin CD et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995; 83: 473–482.PubMedCrossRefGoogle Scholar
  37. 37.
    Yamagata K, Andreasson KI, Kaufman WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons; regulation by synaptic activity and glucocorticoids. Neuron. 1993; 11: 371–386.PubMedCrossRefGoogle Scholar
  38. 38.
    Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol. 1995; 355: 296–315.PubMedCrossRefGoogle Scholar
  39. 39.
    Breder CD, Saper CB. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res. 1996; 713: 64–69.PubMedCrossRefGoogle Scholar
  40. 40.
    Cao C, Matsumura K, Yamagata K, Watanabe Y. Endothelial cells of the brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1β: a possible site of prostaglandin synthesis responsible for fever. Brain Res. 1996; 733: 263–272.PubMedCrossRefGoogle Scholar
  41. 41.
    Cao C, Matsumura K, Yamagata K, Watanabe Y. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res. 1995; 697: 187–196.PubMedCrossRefGoogle Scholar
  42. 42.
    Marcheselli VL, Bazan NG. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. J Biol Chem. 1996; 271: 24794–24799.PubMedCrossRefGoogle Scholar
  43. 43.
    Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 1996; 390: 165–169.PubMedCrossRefGoogle Scholar
  44. 44.
    Milton AS. Antipyretic actions of aspirin. In: Vane JR, Botting RM, eds. Aspirin and Other Salicylates. London: Chapman and Hall, 1992: 213–244.Google Scholar
  45. 45.
    Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, Otomo S. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects which causes minimal stomach lesions. Gen Pharmacol. 1993; 24: 105–110.PubMedCrossRefGoogle Scholar
  46. 46.
    Yan SD, Zhu H, Fu J et al. Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA. 1997; 94: 5296–5301.PubMedCrossRefGoogle Scholar
  47. 47.
    Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997; 48: 626–632.PubMedCrossRefGoogle Scholar
  48. 48.
    Tomlinson A, Appleton I, Moore AR et al. Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br J Pharmacol. 1994; 113: 693–694.PubMedCrossRefGoogle Scholar
  49. 49.
    Hatanaka K, Harada Y, Kawamura M, Ogino M, Saito M, Katori M. Cell types expressing COX-2 in rat carrageenin-induced pleurisy. Jap J Pharmacol. 1996; 71(Suppl I): 304P.Google Scholar
  50. 50.
    Chida M, Voelkel NF. Effects of acute and chronic hypoxia on rat lung cyclooxygenase. Am J Physiol 1996; 270: L872–L878.PubMedGoogle Scholar
  51. 51.
    O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993; 330: 156–160.PubMedGoogle Scholar
  52. 52.
    Asano K, Lilly CM, Drazen JM. Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. Am J Physiol 1996; 271: L126–L131.PubMedGoogle Scholar
  53. 53.
    Walenga RW, Kester M, Coroneos E, Butcher S, Dwivedi R, Statt C. Constitutive expression of prostaglandin endoperoxide G/H synthase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro. Prostaglandins. 1996; 52: 341–359.PubMedCrossRefGoogle Scholar
  54. 54.
    Samet JM, Reed W, Ghio AJ et al. Induction of prostaglandin H synthase 2 in human airway epithelial cells exposed to residual oil fly ash. Toxicol Appl Pharmacol. 1996; 141: 159–168.PubMedGoogle Scholar
  55. 55.
    Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy. 1997; 17(1 Pt2): 3S–12S.PubMedGoogle Scholar
  56. 56.
    Liu SF, Newton R, Evans TW, Barnes PJ. Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci. 1996;90:301–306.PubMedGoogle Scholar
  57. 57.
    Senna GE, Passalacqua G, Andri G et al. Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Drug Safety. 1996; 14: 94–103.PubMedCrossRefGoogle Scholar
  58. 58.
    Parnham MJ. COX-2 inhibitors at the 8th International Conference of the Inflammation Research Association. Exp Opin Invest Drugs. 1997; 6: 79–82.CrossRefGoogle Scholar
  59. 59.
    Bennett P, Slater D. COX-2 expression in labour. In: Vane J, Botting J, Botting R, eds. Improved Non-steroid Anti-inflammatory Drugs. COX-2 Enzyme Inhibitors. Lancaster Kluwer Academic Publishers, and London William Harvey Press, 1996; 167–188.Google Scholar
  60. 60.
    Langenbach R, Morham SG, Tiano HF et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995; 83: 483–492.PubMedCrossRefGoogle Scholar
  61. 61.
    Gibb W, Sun M. Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol. 1996; 150: 497–503.PubMedCrossRefGoogle Scholar
  62. 62.
    Trautman MS, Edwin SS, Collmer D, Dudley DJ, Simmons D, Mitchell MD. Prostaglandin H synthase-2 in human gestational tissues: Regulation in amnion. Placenta. 1996; 17: 239–245.PubMedCrossRefGoogle Scholar
  63. 63.
    Toth P, Li X, Lei ZM, Rao CV. Expression of human chorionic gonadotropin (hCG)/luteinizing hormone receptors and regulation of the cyclooxygenase-1 gene by exogenous hCG in human fetal membranes. J Clin Endocrinol Metab. 1996; 81: 1283–1288.PubMedCrossRefGoogle Scholar
  64. 64.
    Dinchuk JE, Car BD, Focht RJ et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995; 378: 406–409.PubMedCrossRefGoogle Scholar
  65. 65.
    Chakraborty I, Das SK, Wang J, Dey SK. Developmental expression of the cyclooxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol. 1996; 16: 107–122.PubMedCrossRefGoogle Scholar
  66. 66.
    Narumiya S, Murata T, Hirata M et al. Targeted disruption of genes for the mouse prostanoid receptors. Prost Leuk Essen Fatty Acids. 1996; 55(Suppl 1): 41.Google Scholar
  67. 67.
    Zakar T, Hirst JJ, Milovic JE, Olson DM. Glucocorticoids stimulate the expression of prostaglandin endoperoxide H synthase-2 in amnion cells. Endocrinology. 1995; 136: 1610–1619.PubMedCrossRefGoogle Scholar
  68. 68.
    Spaziani EP, Lantz ME, Benoit RR, O’Brien WF. The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4. Prostaglandins. 1996; 51: 215–223.PubMedCrossRefGoogle Scholar
  69. 69.
    McLaren WJ, Young IR, Wong MH, Rice GE. Expression of prostaglandin G/H synthase-1 and-2 in ovine amnion and placenta following glucocorticoid-induced labour onset. J Endocrinol. 1996; 151: 125–135.PubMedCrossRefGoogle Scholar
  70. 70.
    Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343: 769–772.PubMedCrossRefGoogle Scholar
  71. 71.
    Langman MJS, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343: 1075–1078.PubMedCrossRefGoogle Scholar
  72. 72.
    Henry D, Lim LL-Y, Rodriguez LAG et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br Med J. 1996; 312: 1563–1566.CrossRefGoogle Scholar
  73. 73.
    Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995; 44: 1–10.PubMedCrossRefGoogle Scholar
  74. 74.
    Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors. Inflamm Res. 1995; 44: 253–257.PubMedCrossRefGoogle Scholar
  75. 75.
    Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993; 90: 11693–11697.PubMedCrossRefGoogle Scholar
  76. 76.
    Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and-2 by non-steroidal anti-inflammatory drugs. J Pharmacol Exp Therap. 1994; 271: 927–934.Google Scholar
  77. 77.
    Churchill L, Graham AG, Shih C-K, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology. 1996; 4: 125–135.CrossRefGoogle Scholar
  78. 78.
    Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and-2 by non-steroidal anti-inflammatory drugs. J Physiol Pharmacol. 1997; 48 (in press).Google Scholar
  79. 79.
    Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol. 1996; 25(Suppl 102): 29–37.CrossRefGoogle Scholar
  80. 80.
    Tavares IA, Bennett A. Activity of nimesulide on constitutive and inducible prostaglandin cyclo-oxygenase. Int J Tissue React. 1993; 15: 49.PubMedGoogle Scholar
  81. 81.
    Young JM, Panah S, Satchawatcharaphong C, Cheung PS. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and-2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996; 45: 246–253.PubMedCrossRefGoogle Scholar
  82. 82.
    Weissenbach, R. Clinical trials with nimesulide, a new non-steroid anti-inflammatory agent, in rheumatic pathology. J Int Med Res. 1981; 13: 237–245.Google Scholar
  83. 83.
    Pais JM, Rosteiro FM. Nimesulide in the short-term treatment of the inflammatory process of dental tissues: A double-blind controlled trial against oxyphenbutazone. J Int Med Res. 1983; 11: 149–154.PubMedGoogle Scholar
  84. 84.
    Emami Nouri E. Nimesulide for treatment of acute inflammation of the upper respiratory tract. Clin Ther. 1984; 6: 142–150.Google Scholar
  85. 85.
    Fusetti G, Magni E, Armandola MC. Tolerability of nimesulide. Epidemiological data. Drugs. 1993; 46(Suppl 1): 277–280.Google Scholar
  86. 86.
    Glaser K, Sung M-L, O’Neill K et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 1995; 281: 107–111.PubMedCrossRefGoogle Scholar
  87. 87.
    Laine L, Sloane R, Ferretti M, Cominelli F. A randomised double-blind comparison of placebo, etodolac and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 1995; 42: 428–433.PubMedCrossRefGoogle Scholar
  88. 88.
    Cummings DM, Amadio P Jr. A review of selected newer non-steroidal anti-inflammatory drugs. Am Fam Physician. 1994; 49: 1197–1202.PubMedGoogle Scholar
  89. 89.
    Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994; 91: 12013–12017.PubMedCrossRefGoogle Scholar
  90. 90.
    Chan C-C, Boyce S, Brideau C et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther. 1995; 274: 1531–1537.PubMedGoogle Scholar
  91. 91.
    Hubbard RC, Mehlisch DR, Jasper DR, Nugent MJ, Yu S, Isakson PC. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J Invest Med. 1996; 44: 293A.Google Scholar
  92. 92.
    Needleman P. Development of novel COX-2 inhibitors. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Abstracts of the William Harvey Research Conference, Cannes. 1997: 24.Google Scholar
  93. 93.
    Boyce S, Chan C-C, Gordon R et al. L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacology. 1994; 33: 1609–1611.PubMedCrossRefGoogle Scholar
  94. 94.
    Ford-Hutchinson A. New highly selective COX-2 inhibitors. In: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Abstracts of the William Harvey Research Conference, Cannes. 1997: 23.Google Scholar
  95. 95.
    Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol. 1996; 25(Suppl 102): 3–8.CrossRefGoogle Scholar
  96. 96.
    Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993; 268: 6610–6614.PubMedGoogle Scholar
  97. 97.
    Klein T, Nüsing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol. 1994; 48: 1605–1610.PubMedCrossRefGoogle Scholar
  98. 98.
    Futaki N, Takahashi S, Yokoyama M, Arai S, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994; 47: 55–59.PubMedCrossRefGoogle Scholar
  99. 99.
    O’Neill GP, Mancini JA, Kargman S et al. Overexpression of human prostaglandin G/H synthase-1 and-2 by recombinant vaccinia virus: inhibition by non-steroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol. 1994; 45: 245–254.PubMedGoogle Scholar
  100. 100.
    Gierse JK, Hauser SD, Creely DP et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995; 305: 479–484.PubMedGoogle Scholar
  101. 101.
    Engelhardt G, Bögel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol. 1996; 51: 21–28.Google Scholar
  102. 102.
    Patrignani P, Panara MR, Greco A et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994; 271: 1705–1712.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • J. R. Vane
  • R. M. Botting

There are no affiliations available

Personalised recommendations